FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1995066852> ?p ?o ?g. }

• W1995066852 endingPage "564" @default.
• W1995066852 startingPage "551" @default.
• W1995066852 abstract "Cyclic GMP, guanosine 3′,5′-cyclic monophosphate, is a critical and multifunctional second-messenger molecule that mediates diverse physiological and pathophysiological functions in cardiac and vascular tissues. Synthesized through nitric oxide, carbon monoxide, and/or natriuretic peptide-mediated guanylate cyclase stimulation and guanosine triphosphate dephosphorylation, cyclic GMP is capable of stimulating a cascade of serine/threonine kinase events, including signaling through cyclic GMP- and/or cyclic AMP-dependent protein kinases, eliciting protein kinase-independent actions such as modulation of ion channels or transporters, or undergoing hydrolytic degradation through actions of cyclic GMP-regulated phosphodiesterases. Substrates, enzymes, cofactors, and associated variables in this multifaceted system have historically been targets of vital pharmacotherapies with perhaps most common the use of vascular smooth muscle-targeting organonitrates in cardiac patients and phosphodiesterase inhibitors in individuals with erectile dysfunction. Accumulating basic science and clinical evidence, however, suggests that cyclic GMP signaling is compromised under conditions of disease or elevated physiological stresses. Moreover, nitric oxide can stimulate an array of cytotoxic effects and nitric oxide-based therapies can be limited by diminished bioactivity and the development of tachyphylaxis or tolerance after prolonged use. Consequently, an emerging area for clinical drug development and therapeutic drug evaluation for conditions of cardiovascular adversity has focused on identification of cyclic GMP signaling pathways that act under oxidized or nitric oxide-unresponsive conditions and/or that operate irrespective of nitric oxide-induced complications. The aim of this therapeutic review is to describe novel, nitric oxide-alternate avenues for cyclic GMP signaling in vascular smooth muscle growth with particular emphasis on pharmacotherapeutics of recently characterized cyclic GMP-specific approaches." @default.
• W1995066852 created "2016-06-24" @default.
• W1995066852 creator A5005382945 @default.
• W1995066852 date "2008-11-01" @default.
• W1995066852 modified "2023-10-14" @default.
• W1995066852 title "Novel Therapies for Cyclic GMP Control of Vascular Smooth Muscle Growth" @default.
• W1995066852 cites W1528925569 @default.
• W1995066852 cites W1583052190 @default.
• W1995066852 cites W1586487499 @default.
• W1995066852 cites W1621595817 @default.
• W1995066852 cites W1821918060 @default.
• W1995066852 cites W1968791438 @default.
• W1995066852 cites W1970467033 @default.
• W1995066852 cites W1972048560 @default.
• W1995066852 cites W1986525923 @default.
• W1995066852 cites W1991957474 @default.
• W1995066852 cites W1992718978 @default.
• W1995066852 cites W1994561091 @default.
• W1995066852 cites W2002109628 @default.
• W1995066852 cites W2004214604 @default.
• W1995066852 cites W2007737411 @default.
• W1995066852 cites W2011390031 @default.
• W1995066852 cites W2015132829 @default.
• W1995066852 cites W2019545674 @default.
• W1995066852 cites W2021785566 @default.
• W1995066852 cites W2028569503 @default.
• W1995066852 cites W2028778467 @default.
• W1995066852 cites W2033320084 @default.
• W1995066852 cites W2035550438 @default.
• W1995066852 cites W2040072601 @default.
• W1995066852 cites W2045315460 @default.
• W1995066852 cites W2045996823 @default.
• W1995066852 cites W2054935021 @default.
• W1995066852 cites W2062573433 @default.
• W1995066852 cites W2064063264 @default.
• W1995066852 cites W2069688010 @default.
• W1995066852 cites W2069881405 @default.
• W1995066852 cites W2083043369 @default.
• W1995066852 cites W2089968377 @default.
• W1995066852 cites W2095045934 @default.
• W1995066852 cites W2096644059 @default.
• W1995066852 cites W2101093001 @default.
• W1995066852 cites W2103094013 @default.
• W1995066852 cites W2107031234 @default.
• W1995066852 cites W2112906404 @default.
• W1995066852 cites W2113691971 @default.
• W1995066852 cites W2116403540 @default.
• W1995066852 cites W2128304597 @default.
• W1995066852 cites W2131280359 @default.
• W1995066852 cites W2147416357 @default.
• W1995066852 cites W2149407335 @default.
• W1995066852 cites W2152845778 @default.
• W1995066852 cites W2160792415 @default.
• W1995066852 cites W2169182236 @default.
• W1995066852 cites W2188389775 @default.
• W1995066852 cites W2205467546 @default.
• W1995066852 cites W2309380696 @default.
• W1995066852 cites W2327999505 @default.
• W1995066852 cites W2467657054 @default.
• W1995066852 cites W2615043561 @default.
• W1995066852 cites W304581165 @default.
• W1995066852 doi "https://doi.org/10.1097/mjt.0b013e318140052f" @default.
• W1995066852 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2677189" @default.
• W1995066852 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19127140" @default.
• W1995066852 hasPublicationYear "2008" @default.
• W1995066852 type Work @default.
• W1995066852 sameAs 1995066852 @default.
• W1995066852 citedByCount "18" @default.
• W1995066852 countsByYear W19950668522012 @default.
• W1995066852 countsByYear W19950668522013 @default.
• W1995066852 countsByYear W19950668522015 @default.
• W1995066852 countsByYear W19950668522016 @default.
• W1995066852 countsByYear W19950668522017 @default.
• W1995066852 countsByYear W19950668522018 @default.
• W1995066852 countsByYear W19950668522021 @default.
• W1995066852 crossrefType "journal-article" @default.
• W1995066852 hasAuthorship W1995066852A5005382945 @default.
• W1995066852 hasBestOaLocation W19950668522 @default.
• W1995066852 hasConcept C134018914 @default.
• W1995066852 hasConcept C163235415 @default.
• W1995066852 hasConcept C181199279 @default.
• W1995066852 hasConcept C184235292 @default.
• W1995066852 hasConcept C185592680 @default.
• W1995066852 hasConcept C199217515 @default.
• W1995066852 hasConcept C2779395532 @default.
• W1995066852 hasConcept C2780994212 @default.
• W1995066852 hasConcept C2992686903 @default.
• W1995066852 hasConcept C519581460 @default.
• W1995066852 hasConcept C55493867 @default.
• W1995066852 hasConcept C62478195 @default.
• W1995066852 hasConcept C62826618 @default.
• W1995066852 hasConcept C71924100 @default.
• W1995066852 hasConcept C82495950 @default.
• W1995066852 hasConcept C97029542 @default.
• W1995066852 hasConcept C98274493 @default.
• W1995066852 hasConceptScore W1995066852C134018914 @default.
• W1995066852 hasConceptScore W1995066852C163235415 @default.
• W1995066852 hasConceptScore W1995066852C181199279 @default.

• next